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Rationale
• Anemia is prevalent in CKD, worsening with its progression1,2
• A substantial proportion of people with CKD lack sufficient iron stores to support 
erythropoiesis
• Current treatment options for IDA have limitations: 
• Oral ferrous products may be poorly tolerated because of GI AEs3
• Intravenous iron administration can be inconvenient and risks iron overload and 
allergic reactions4,5
• Ferric maltol is an oral iron-replacement therapy for IDA formulated to improve GI 
absorption
AE, adverse event; CKD, chronic kidney disease; GI, gastrointestinal; IDA, iron-deficiency anemia.
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Key inclusion criteria: 
• eGFR ≥15 to <60 mL/min/1.73 m2
• Hb ≥8.0 to <11.0 g/dL 
and ferritin <250 μg/L + TSAT <25%
or ferritin <500 μg/L + TSAT <15%
AE, adverse event; BID, twice daily; eGFR, estimated glomerular filtration rate; Hb, hemoglobin; SAE, serious adverse event; TSAT, transferrin saturation.
AEGIS-CKD: phase III trial to evaluate the efficacy of oral ferric maltol vs 
placebo to treat IDA in patients with stage 3 or 4 CKD











(up to week 52)
12 52
Stratification
by Hb and eGFR
2:1
Primary efficacy endpoint Secondary efficacy endpoints include:
• Change in Hb concentration from 
baseline to week 16
• ≥1 g/dL and ≥2 g/dL Hb increases at week 16
• Hb ≥11 g/dL at week 16
• Hb changes from baseline to week 4 and week 8
• Changes in ferritin, TSAT and serum iron
• Treatment-emergent AEs and SAEs
Patient demographics and baseline disease characteristics 
(ITT population)





Age, years Mean (SD) 68.5 (12.4) 65.2 (12.8) 67.4 (12.6)
Sex, n (%) Female 78 (70.3) 39 (69.6) 117 (70.1)
Male 33 (29.7) 17 (30.4) 50 (29.9)
Race, n (%) Asian 2 (1.8) 0 2 (1.2)
American Indian 1 (0.9) 0 1 (0.6)
African American 23 (20.7) 12 (21.4) 35 (21.0)
White 81 (73.0) 42 (75.0) 123 (73.7)
Other 4 (3.6) 2 (3.6) 6 (3.6)
Hb, g/dL Mean (SD) 10.06 (0.769) 10.03 (0.817) 10.05 (0.783)
<9.5, n (%) 21 (18.9) 11 (19.6) 32 (19.2)
≥9.5, n (%) 90 (81.1) 45 (80.4) 135 (80.8)
eGFR, mL/min/1.73 m2 Mean (SD) 31.9 (11.53) 29.7 (10.56) 31.1 (11.23)
≤30, n (%) 59 (53.2) 30 (53.6) 89 (53.3)
>30, n (%) 52 (46.8) 26 (46.4) 78 (46.7)
eGFR, estimated glomerular filtration rate; Hb, hemoglobin; ITT, intent-to-treat.
Primary endpoint: change in Hb concentration from baseline to 










































• Difference for ferric maltol vs placebo:
• LSM (SE): 0.52 (0.210)
• 95% CI: 0.102–0.930
• p=0.0149
CI, confidence interval; Hb, hemoglobin; ITT, intent-to-treat; LSM, least-squares mean; SE, standard error.
Secondary efficacy analyses (ITT population)
Ferric maltol Placebo Ferric maltol vs placebo p value
Hb levels at week 16, % patients Adjusted odds ratio (95% CI)
≥1 g/dL change from baseline 19.8 8.9 2.48 (0.86–7.14) 0.0923
≥2 g/dL change from baseline 6.3 0.0 NC* NC*
≥11 g/dL 26.0 17.5 2.60 (1.02–6.60) 0.0442
Iron parameters: changes from
baseline to week 16
LSM difference (SE)
(95% CI)
Ferritin, µg/dL 25.49 (5.400) –8.25 (7.614) 33.73 (9.354)(15.264–52.205) 0.0004








*As the placebo group had no patients who met the criteria, the odds ratio was not calculated.
CI, confidence interval; Hb, hemoglobin; ITT, intent-to-treat; LSM, least-squares mean; NC, not calculated; SE, standard error; TSAT, transferrin saturation.
Adverse events (safety population)
• A higher proportion of patients on ferric maltol vs placebo completed 16 weeks of treatment:
• Ferric maltol 81% (n=90/111)





Patients with treatment-emergent adverse events (TEAEs) % patients % patients
Any TEAE (deemed related to study drug) 67.6 (18.9) 75.0 (10.7)
Serious TEAE (deemed related to study drug) 20.7 (0) 21.4 (0)
TEAE resulting in death (deemed related to study drug) 0.9 (0) 1.8 (0)
TEAE resulting in treatment withdrawal (deemed related to study drug) 6.3 (2) 8.9 (2)
Adverse events (safety population)
Ferric maltol (n=111) Placebo (n=56)
Adverse events affecting ≥5% of patients % patients % patients




Feces discolored 7.2 1.8
Metabolism and nutrition disorders 18.9 23.2
Hyperkalemia 3.6 12.5
Infections and infestations 15.3 23.2
Urinary tract infection 6.3 8.9
Renal and urinary disorders 9.0 10.7
Acute kidney injury 4.5 7.1
Blood and lymphatic system disorders 4.5 16.1
Anemia 3.6 10.7
Conclusion
• Oral ferric maltol resulted in statistically significant and clinically meaningful 
increases in hemoglobin concentration, and in all iron parameters, from baseline 
to week 16 vs placebo, supporting the efficacy of oral ferric maltol in treating IDA 
in patients with stage 3 or 4 CKD
• Ferric maltol was generally well tolerated with a lower rate of discontinuation due 
to AEs than placebo. Only minor differences were noted in the safety profile and 
overall GI AEs vs placebo
AEs, adverse events; CKD, chronic kidney disease; GI, gastrointestinal; IDA, iron-deficiency anemia.
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